The GHRH antagonist MIA-602 produced anxiolytic and antidepressant-like effects in mice over 4 weeks by reducing brain inflammation and oxidative stress through Nrf2 and BDNF pathways.
New mechanism: inflammation → moodMIA-602 treats mood disorders through anti-inflammatory and antioxidant pathways (Nrf2, BDNF) rather than serotonin — a fundamentally different approach from existing antidepressants.
What the researchers found
GHRH antagonist MIA-602 produced anxiolytic and antidepressant effects in mice after 4 weeks of subcutaneous treatment, mediated through Nrf2 and BDNF signaling in the hippocampus and prefrontal cortex.
Why it matters
Current antidepressants and anti-anxiety drugs do not work for everyone and can have significant side effects. GHRH antagonists represent a completely different approach that targets inflammation and oxidative stress rather than serotonin or other traditional pathways.
The numbers in context
4 weeks subcutaneous treatment; increased Nrf2 and BDNF in hippocampus and prefrontal cortex; anti-inflammatory and antioxidant effects confirmed
How the study worked
Animal study in adult mice. MIA-602 was given subcutaneously for 4 weeks. Tested anxiety and depression-like behaviors using standard behavioral tests. Measured inflammatory markers, oxidative stress, Nrf2, and BDNF in brain tissue.
Who was studied
Adult mice with induced anxiety and depression-like behaviors
What this study cannot tell us
Animal study only. Mouse models of anxiety and depression do not fully replicate human mood disorders. No comparison to existing antidepressant or anti-anxiety drugs. Long-term effects and safety are unknown.
How to read the evidence
This is a preclinical animal study using behavioral tests and brain tissue analysis in mice. While published in the high-impact journal Molecular Psychiatry, the findings require human clinical validation before any therapeutic conclusions.
When this study was published
Published in 2021, this study was part of the emerging research connecting GHRH peptide antagonists to neuropsychiatric applications. Published in Molecular Psychiatry (high impact factor), it signals serious academic interest in this approach.
The bigger picture
GHRH antagonists were originally developed as anti-cancer agents (as seen in another study by Schally's group). The discovery that they also have anxiolytic and antidepressant properties represents a surprising and potentially transformative finding. If GHRH peptide antagonists can treat mood disorders through anti-inflammatory and neuroprotective mechanisms, they would represent an entirely new class of psychiatric medication — one targeting the inflammation-mental illness connection rather than the monoamine pathways of current drugs.
Questions still open
- Would MIA-602 be effective in human PTSD or treatment-resistant depression where inflammation is a known factor?
- How do the anxiolytic effects of GHRH antagonists compare to existing benzodiazepines or SSRIs in strength and onset?
- Could GHRH antagonists be used as adjuncts to existing psychiatric medications for enhanced efficacy?
Common questions
How is GHRH antagonist different from regular antidepressants?
Could this help with PTSD?
Read the original research
Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD.
Molecular psychiatry, 26(12), 7465-7474
Citation
Recinella, Lucia; Chiavaroli, Annalisa; Orlando, Giustino; Ferrante, Claudio; Veschi, Serena; Cama, Alessandro; Marconi, Guya Diletta; Diomede, Francesca; Gesmundo, Iacopo; Granata, Riccarda; Cai, Renzhi; Sha, Wei; Schally, Andrew V; Brunetti, Luigi; Leone, Sheila. (2021). Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD.. Molecular psychiatry, 26(12), 7465-7474. https://doi.org/10.1038/s41380-021-01228-5